Citations

Clear

17 citation(s) found for "Sra, Manraj".

Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Kumar, Shaji, Sra, Manraj Singh , Singh, Manraj

Mayo Clinic

Expert Opinion on Biological Therapy | July 11, 2026 | Volume: 26 | Issue: 7 | Pages: 665-676

10.1080/14712598.2026.2703858 | PMID 42434875 Get It

Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli, Karthik , Ito, Satoko , Ng, Ding Quan , Singh, Manraj , Wang, Daniel , Krumholz, Harlan M. , Krishnamurti, Lakshmanan , Goshua, George , Wang, Daniel , Sra, Manraj Singh , Goshua, George , Krumholz, Harlan M. , Krishnamurti, Lakshmanan , Pandya, Ankur

Mayo Clinic

Blood | June 2, 2026 | Volume: 148 | Issue: 7 | Pages: 896-909

10.1182/blood.2025032290 | PMID 42227898 Get It

Abstract Nonmyeloablative-related haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT) has emerged as an additional treatment to achieve durable remission in sickle cell disease (SCD), a prevalent blood disorder characterized by painful vaso-occlusive crises and chronic anemia. The standard of care (SOC) for SCD includes hydroxyurea, pain management, and blood transfusion, but patients with SCD still lose several decades of life expectancy. Gene therapy (GT) for SCD is the other treatment for lifelong disease amelioration in SCD, with accessibility limited by cost and manufacturing capacity in the United States and globally. Two recent prospective studies that evaluated NMAC-HID allo-HSCT validated haploidentical allotransplantation as an efficacious and accessible treatment option in the era of GT. Given the ongoing price negotiation across jurisdictions for GT implementation and the absence of cost-effectiveness data comparing NMAC-HID allo-HSCT and GT, we conducted a cost-effectiveness analysis of NMAC-HID allo-HSCT vs GT vs SOC for adults and children living with SCD. The primary outcomes were the incremental cost-effectiveness ratio and the net monetary benefits across these 3 strategies. The secondary outcome was the maximum cost-effective threshold price for GT compared with NMAC-HID allo-HSCT. Treatment with SOC, NMAC-HID allo-HSCT, and GT accrued 14.3, 20.1, and 22.1 quality-adjusted life-years at costs of $1.22 million, $1.15 million, and $2.75 million, respectively. NMAC-HID allo-HSCT was the cost-effective strategy compared with GT in 100% of 10 000 Monte Carlo iterations across the base case and all scenario analyses. The maximum cost-effective thresholds for GT vs SOC were $1.4 million in the United States and $4200 to $22 000 across India, Nigeria, and Tanzania, depending on willingness-to-pay thresholds.
Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds
Wang, Daniel , Singh, Manraj , Ng, Ding Quan , Tadepalli, Aniketh, Rinaldi, Kristina , Cuker, Adam, Goshua, George , Wang, Daniel , Sra, Manraj Singh , Cuker, Adam , Goshua, George , Ito, Satoko , Cuker, Adam

Mayo Clinic

Blood Advances | May 28, 2026 | Volume: 10 | Issue: 16 | Pages: 5644-5652

10.1182/bloodadvances.2026020143 | PMID 42206692 Get It

Abstract Maternal iron deficiency (ID) affects nearly 85% of all pregnancies worldwide by the third trimester and is strongly linked with maternal morbidity, poor birth outcomes, and cognitive and behavioral developmental deficits in children. Despite its burden on maternofetal health, no guidelines exist for routine screening of ID in pregnant individuals in the United States. The World Health Organization uses a diagnostic (ie, nonscreening) ferritin threshold of 15 μg/L for ID in the first trimester of pregnancy, with no guidance for the second and third trimesters. Routine screening for ID in pregnancy could identify a large proportion of mothers who remain undiagnosed and untreated under the current clinical status quo. Accordingly, we conducted, to our knowledge, the first cost-effectiveness analysis of ferritin-based ID screening in pregnant women in the United States, comparing thresholds of (1) 30 μg/L vs (2) 15 μg/L vs (3) no screening from a modified US societal perspective accounting for wages lost to infusion time, infusion administration costs, and the cost of annual hematology follow-up. We found that screening at 30 μg/L was the preferred strategy across extensive base-case, threshold, and sensitivity analyses and across all examined willingness-to-pay thresholds, with an incremental cost-effectiveness ratio of $34 000/quality-adjusted life year (QALY; 95% credible interval, $32 000-$36 200/QALY) compared with no screening. No parameter variation changed this outcome, and screening at 30 μg/L was favored in 100% of 10 000 Monte Carlo iterations. Population-level regular second- and third-trimester screening for ID using physiologically informed ferritin ranges should be considered for all pregnant women in the United States.
Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Rasheed, Azgar Abdul , Ganguly, Shuvadeep, Singh, Manraj, Sreenivas, Vishnubhatla , Pillai, Ashwati S., Joison, Anu Theresa, Sharma, Swetambri , Bakhshi, Sameer , Singh, Manraj , Sra, Manraj Singh , Ganguly, Shuvadeep , Kumar, Santhosh E. , Batra, Atul , Pushpam, Deepam

Mayo Clinic

Pediatric Blood & Cancer | March 13, 2026 | Volume: 73 | Issue: 5 | Pages: No page available

10.1002/1545-5017.70171 | PMID 41823195 Get It

ABSTRACT Background Fosaprepitant is non‐inferior to aprepitant in adults receiving highly emetogenic chemotherapy (HEC). We evaluated whether fosaprepitant is non‐inferior to aprepitant in children receiving HEC. Methods In this open‐label, non‐inferiority trial, children aged 5–18 years, receiving their first cycle of HEC, were randomized 1:1 to the fosaprepitant or aprepitant group. The fosaprepitant group received a single intravenous dose of 4 mg/kg (max 150 mg). The aprepitant group received oral aprepitant capsules (weight 15 to <30 kg: 80 mg Days 1–3; weight ≥30 kg, or age ≥12 years: 125 mg Day 1, 80 mg Days 2 and 3). Both groups received ondansetron and dexamethasone. The primary outcome was the complete response (CR) rate of vomiting during the acute phase (AP) with a non‐inferiority margin of 15%. Secondary outcomes included CR rates in the delayed (DP) and overall phases (OP), grade of vomiting, incidence and severity of nausea, and adverse effects. Results A total of 279 children were included in the modified intention‐to‐treat analysis (fosaprepitant group: 140; aprepitant group: 139). In AP, the difference of CR rate between fosaprepitant [76 (54.3%)] and aprepitant groups [84 (60.4%)] was −6.1% [90% CI: −15.7% to +3.6%], with the lower limit exceeding −15%, failing to establish non‐inferiority. The CR rate with fosaprepitant versus aprepitant was 62.1% ( n = 87) versus 65.5% ( n = 91) in DP (difference: –3.4%; 90% CI: –12.7% to 6.1%) and 42.9% ( n = 60) versus 49.6% ( n = 69) in the OP (difference: –6.7%; 90% CI: –16.5% to 3.1%). Grade of vomiting, incidence and severity of nausea, and adverse effects were similar between the two groups. Conclusions Non‐inferiority of fosaprepitant compared to aprepitant was not demonstrated in children undergoing their first cycle of HEC. Trial Registration Clinical Trials Registry, India (CTRI/2019/05/019082).
Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding
Wang, Daniel , Singh, Manraj , Ito, Satoko, Ng, Ding Quan , Glaeser-Khan, Samira, Wang, Daniel , Hirniak, Sam , Lee, Alfred Ian , Cuker, Adam, Goshua, George , Sra, Manraj Singh , Glaeser‐Khan, Samira , Cuker, Adam , Goshua, George , Ito, Satoko , Cuker, Adam

Mayo Clinic

Blood Advances | January 8, 2026 | Volume: 10 | Issue: 5 | Pages: 1508-1517

10.1182/bloodadvances.2025018315 | PMID 41504430 Get It

Abstract Iron-deficiency anemia (IDA) affects nearly one-third of women globally, with heavy menstrual bleeding (HMB) being a significant risk factor among those of reproductive age. Despite the substantial burden of HMB-related IDA, patients often face delays in receiving effective treatment. Oral iron is typically used as first-line therapy, despite frequent gastrointestinal side effects and challenges in treatment adherence. This study evaluated the reproductive life span cost-effectiveness of first-line intravenous (IV) vs oral iron therapy for women with HMB and IDA. We developed a Markov model simulating a cohort of women aged 18 to 51 years, comparing first-line treatment with IV iron dextran, IV ferumoxytol, IV iron sucrose, or oral ferrous sulfate. Costs and quality-adjusted life years (QALYs) were estimated from the societal perspective. IV iron dextran was the cost-effective treatment, yielding 19.26 QALYs at a cost of $157 500, compared with 19.10 QALYs at $152 900 for oral ferrous sulfate. The incremental cost-effectiveness ratio for IV iron dextran was $28 600 per QALY. Treatment with IV ferumoxytol and iron sucrose cost $158 300 and $163 500, respectively, and did not provide additional QALY benefit compared with IV iron dextran, which remained the cost-effective treatment across a range of scenarios and sensitivity analyses. Our findings indicate that first-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds. These results support expanding access to IV iron as a first-line option, and highlight the need to reduce treatment delays and insurance-related barriers.
Raising the bar in maternofetal hematology: Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds
Sra, Manraj, Cuker, Adam , Wang, Daniel , Sra, Manraj, Ito, Satoko , Goshua, George

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 598-598

10.1182/blood-2025-598 Get It

Abstract Introduction: Iron deficiency (ID) is among the five leading causes of years lived with disability in women of reproductive age worldwide and affects &gt;50% of pregnancies. Both ID and its terminal sequela, iron deficiency anemia, are associated with adverse maternal-fetal outcomes including postpartum hemorrhage, impaired fetal neurocognitive development, preterm labor, and maternal mortality. At present, no United States (US) guidelines exist for the universal screening of ID in pregnancy. Moreover, diagnostic thresholds for ID established by the Centers for Disease Control and Prevention (CDC; &lt;15µg/L ferritin in all trimesters) and the World Health Organization (WHO; &lt;15µg/L ferritin in first trimester and no guidance in second or third) fall below more sensitive physiologically-based thresholds of no less than 20-25µg/L ferritin in pregnancy. As such, ID screening and treatment represents an enormous gap in the health of expectant mothers and in which intravenous iron supplementation has been established as an effective and safe treatment option. We sought to address this gap by conducting the first cost-effectiveness analysis of screening ferritin thresholds for ID diagnosis and treatment in pregnancy. Methods: We built a Markov simulation to examine the cost-effectiveness of screening all individuals for iron deficiency in the second and third trimesters of pregnancy with the following strategies: 1) ferritin threshold &lt;30µg/L, 2) ferritin threshold &lt;15µg/L, and 3) status quo (i.e., no screening). The analysis was conducted over a lifetime horizon, from the US health system perspective and across all accepted willingness-to-pay (WTP) thresholds measured in $ per quality-adjusted-life-year (QALY). Costs were assessed in 2025 USD, inclusive of age- and sex- specific annual healthcare costs informed by the US Medical Expenditures Panel Survey. Age-specific fertility rates were sourced from the US National Vital Statistics Reports and used for model internal validation. The trimester-specific prevalence of ID was informed by the largest published longitudinal prospective cohort study of iron status in pregnant women to date. The probability of iron-related adverse events including anaphylaxis was sourced from the World Health Organization Vigibase data. Aligning with prospective data of ID in pregnancy, women entered the model at age 15 and were screened (or not screened) for ID per treatment strategy during the second and third trimester of each pregnancy in their lifetime. If found to be iron deficient, patients were treated with a single dose of 1g intravenous iron dextran. A separate scenario analysis from a societal perspective also incorporated the cost of wages lost to infusion time. Effectiveness was measured in QALYs and parameterized multiplicatively using age-, sex-, pregnancy-, and ID-specific utility values, exclusively assessing maternal benefit in pregnancy without accounting for any fetal benefit. The primary outcome of interest was the incremental cost-effectiveness ratio (ICER). We conducted deterministic and probabilistic sensitivity analyses, capturing uncertainty across all parameters simultaneously over 10,000 Monte Carlo iterations. Results: Internal model validation demonstrated an average fertility rate of 1.62 [95% credible interval (CI) 1.59-1.65], in line with the US fertility rate of 1.62. Screening for ID with a ferritin threshold of 30µg/L versus 15µg/L versus no screening accrued $213,000, $212,800, and $212,400 and 25.12, 25.11, and 25.09 QALYs per individual, respectively. Screening at a ferritin threshold of 30µg/L was the cost-effective strategy in 100% of 10,000 Monte Carlo iterations, with an ICER of $23,000/QALY [95% CI $20,000-$27,000/QALY], below all accepted WTP thresholds. Screening at 30µg/L remained the cost-effective strategy from a societal perspective, at an ICER of $33,000/QALY [95% CI $29,000-$38,000/QALY]. Deterministic sensitivity analysis revealed that no parameter variations changed this conclusion.Conclusion: The identification and treatment of ID beginning in the second trimester at a ferritin threshold of &lt;30µg/L is the cost-effective intervention, in comparison to a threshold of &lt;15µg/L or no screening. These results fill a critical gap in maternofetal medicine and may help inform the forthcoming American Society of Hematology Clinical Practice Guidelines on the Diagnosis and Treatment of Iron Deficiency.
Cost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance
Sra, Manraj, Sra, Manraj, Chetlapalli, Karthik , Ito, Satoko , Ng, Ding Quan , Patel, Kishan K. , Liu, Yuxin , Goshua, George

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4409-4409

10.1182/blood-2025-4409 Get It

Abstract Introduction: Monoclonal gammopathy of undetermined significance (MGUS) affects over 2 million individuals aged ≥70 in the US. Earlier detection of smoldering multiple myeloma (SMM) and multiple myeloma (MM) in individuals with suspected MGUS via bone marrow biopsy allows for earlier active monitoring and potential intervention, including with daratumumab for high-risk SMM. Risk prediction for the presence of SMM or MM with the iStopMM and Mayo Clinic models leads to decreased individual-patient and population-level resource utilization burden of bone marrow testing with the tradeoff of some missed non-MGUS diagnoses. We sought to quantify the value of earlier diagnosis, while additionally accounting for the recent results of the AQUILA trial, by assessing the lifetime cost-effectiveness of bone marrow testing strategies for patients with suspected MGUS. Methods: In this independent analysis free of industry influence, we used a decision tree with nested Markov cohort models to evaluate diagnosis and disease progression from MGUS and SMM to MM across 3 diagnostic strategies employing: (1) iStopMM risk prediction model versus (2) Mayo Clinic risk stratification and prediction model versus (3) a test-all strategy. Both risk prediction model performance characteristics were derived from the largest population-level prospective cohort study. Individuals in the MGUS state were monitored annually for disease progression with blood tests. The SMM state included two groups: those correctly diagnosed through biopsy and those misclassified as MGUS due to not undergoing biopsy under the prediction model triage rules (missed SMM diagnosis). As recommended by guidelines, diagnosed patients with non–low-risk SMM were monitored with blood tests every three months; those with low-risk SMM were tested every six months. All diagnosed SMM patients underwent imaging for bone lesions at diagnosis and annually for up to five years. Missed SMM patients were monitored at the same frequency as those with MGUS until disease progression. Early versus delayed myeloma diagnosis complications were informed by real-world multi-institutional quasi-experimental data of consecutively diagnosed patients with MM. MM treatment and outcomes across up to four lines of therapy were modeled exactly as previously published in a validated model. In additional scenario analyses, we assessed the impact of daratumumab monotherapy in the care of people with high-risk SMM across all 3 testing strategies by incorporating the progression free survival and overall survival benefit as reported in the phase 3 AQUILA study. The primary outcome was the incremental net monetary benefit (iNMB), reported across all accepted US willingness-to-pay (WTP) thresholds from a US health system perspective. We concluded with extensive deterministic sensitivity analyses and additionally quantified uncertainty across all model parameters simultaneously with 10,000 Monte Carlo simulations. Results: The iStopMM model was the cost-effective strategy yielding the highest NMB of all strategies at every WTP threshold, with per-patient cost and effectiveness of $188,300 and 10.21 QALYs, respectively. This strategy was dominant—costing less and producing more QALYs—than both the Mayo Clinic and test-all strategies. At the population level, use of the iStopMM model over the Mayo Clinic model and the test-all strategy yields iNMBs of $0.67 [95% CI: 0.2 – 1.14] billion and $3.13 [95%CI: 2.80-3.47] billion, respectively, in favor of the iStopMM strategy. The iStopMM strategy was the cost-effective strategy in 100% of 10,000 second order Monte Carlo iterations. In deterministic sensitivity analyses, the top three parameters the iNMB was most sensitive to were prediction model test characteristics (i.e., sensitivity and specificity) as well as the baseline prevalence of SMM. However, no parameter variation could change the conclusion that iStopMM is the cost-effective strategy. In scenario analyses incorporating benefit of daratumumab monotherapy in the care of individuals with high-risk SMM, the iStopMM model remained the cost-effective strategy. Conclusion: Using the iStopMM risk prediction model for marrow sampling in patients with suspected MGUS leads to cost savings per patient evaluated, both with and without incorporating daratumumab benefit in the care of individuals with high-risk SMM, as compared to both the Mayo Clinic model and testing all with bone marrow biopsy.
Risk stratification and early intervention in smoldering multiple myeloma
Singh, Manraj , Kumar, Shaji , Sra, Manraj Singh

Mayo Clinic

Leukemia & Lymphoma | October 24, 2025 | Volume: 67 | Issue: 1 | Pages: 55-63

10.1080/10428194.2025.2576562 | PMID 41133522 Get It

Impact of Gender of the Child on Health Care–Seeking Behavior of Caregivers of Childhood Patients With Cancer: A Mixed-Methods Study
Bhatia, Kanu Priya , Ganguly, Shuvadeep , Sasi, Archana , Singh, Manraj , Malhotra, Sumit , Sharma, Shubhangi , Tahiliani, Bhavika , Verma, Vasudha , Dhania, Tripti, Bisht, Reema, Sharma, Swetambri , Kumari, Mamta , Agarwala, Sandeep , Satapathy, Sujata , Bakhshi, Sameer , Sra, Manraj Singh , Pushpam, Deepam , Bakhshi, Sameer , Verma, Vasudha , Pushpam, Deepam

Mayo Clinic

JCO Global Oncology | September 9, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00325 | PMID 40924975 Get It

PURPOSE Gender bias against girls may affect health-seeking behavior and outcomes of childhood cancer. This study aimed to study the nature and extent of gender bias in health care among caregivers of childhood patients with cancer and also in community. METHODS This cross-sectional mixed-methods study was conducted in a tertiary cancer hospital and an urban community between July 2021 and July 2023. Qualitative component included 26 in-depth interviews (IDI) and four focus group discussions (FGDs) with caregivers of children with cancer. IDIs and FGDs were conducted by a psychologist and continued until thematic saturation was reached. For quantitative part, a gender-bias questionnaire was finalized which was administered to 230 caregivers in hospital and 311 participants from the community, with children in family. RESULTS Most participants did not perceive personal gender bias; however, many acknowledged noticing gender bias in others. This bias was linked to girls being considered financial burdens and having reduced marital prospects due to illness. Reducing treatment costs, improving access, and education targeting societal mindsets were suggested measures to mitigate bias. In community, no significant difference was observed among the respondents based on sex of youngest child in family. However, in hospital, caregivers of male children were less likely to offer similar care to a child of opposite sex than that reported by caregivers of female children ( P = .01) for ailments like fever/diarrhea. Similar difference was not observed for other health care scenarios. CONCLUSION Gender bias against girls, including that in health care access, is influenced by societal norms. Even with little personal perception of bias, there was a significant perceived bias observed in others by the participants. This study identified the existence of gender bias affecting health care choices, including cancer care.
Prevalence and Perception of Complementary and Alternative Medicine Use Among Childhood Cancer Patients: A Mixed‐Methods Study
Ganguly, Shuvadeep , Singh, Manraj , Sasi, Archana , Singh, Ritika , Verma, Vasudha , Sharma, Shubhangi , Das, Anubhav, Pushpam, Deepam , Bakhshi, Sameer , Sra, Manraj Singh , Pushpam, Deepam , Bakhshi, Sameer , Verma, Vasudha, Lohiya, Ayush , Das, Anubhav

Mayo Clinic

Pediatric Blood & Cancer | August 13, 2025 | Volume: 72 | Issue: 11 | Pages: No page available

10.1002/pbc.31975 | PMID 40799010 Get It

ABSTRACTBackgroundComplementary and alternative medicine (CAM) usage among childhood cancer patients remains understudied. Factors associated with CAM use and motivations of caregivers for using CAM remain poorly understood.MethodsThis cross‐sectional mixed‐methods study was conducted among caregivers of patients aged ≤18 years with confirmed cancer diagnoses. Caregivers were interviewed regarding CAM use, reasons for using/non‐using CAM, and views on CAM. Logistic regression identified factors associated with CAM use, whereas qualitative interviews explored motivations and barriers. The impact of CAM usage on 2‐year overall survival was explored.ResultsOut of 450 respondents, CAM usage was reported by 35.78% (n = 161), with home remedies (28.44%, n = 128) and AYUSH (Ayurveda, Unani, Siddha, Yoga, Homeopathy) therapies (13.56%, n = 61) being most common. CAM use was associated with symptom duration ≥30 days (adjusted odds ratio [aOR]: 1.71; 95% CI: 1.09–2.67; p = 0·019) and hematological malignancies (aOR: 2.05; 95% CI: 1.33–3.17; p = 0·001). Major motivations for CAM use included belief in effectiveness (44.72%, n = 72) and family recommendations (34.16%, n = 55). Qualitative interviews highlighted cost, accessibility issues, and diagnostic delays as key drivers of CAM adoption. The 2‐year survival probabilities of CAM users and nonusers were comparable (0.88 [95% CI: 0.83–0.94] vs. 0.87 [95% CI: 0.83–0.92], log‐rank p = 0.75).ConclusionCAM is frequently used by pediatric cancer patients, driven by caregiver beliefs, family influence, and access barriers. Addressing caregiver practices and integrating CAM discussions into care may enhance supportive strategies without impacting survival outcomes.